SCHEDULE: Perceptive Advisors Discloses 7.3% Stake in Alto Neuroscience

Perceptive Advisors and Joseph Edelman have reported a 7.3% beneficial ownership stake in Alto Neuroscience, Inc., totaling 1,989,393 shares.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons beneficially own 1,989,393 shares of Alto Neuroscience, Inc.'s Common Stock.
• This ownership represents 7.3% of the outstanding Common Stock of Alto Neuroscience, Inc.
• The ownership percentage is based on 27,076,629 outstanding shares as of August 8, 2025, as reported in the Issuer's Form 10-Q filed on August 13, 2025.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
• All Reporting Persons share both voting and dispositive power over the 1,989,393 shares.
• The securities were not acquired for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 8

Explanation: The disclosure of a significant 7.3% stake by a reputable life sciences investment firm like Perceptive Advisors is generally viewed as a positive signal, indicating institutional confidence in Alto Neuroscience, Inc. This type of filing does not typically contain negative information.

Positives

• A significant beneficial ownership stake of 7.3% by Perceptive Advisors, a prominent life sciences investment firm, signals institutional confidence in Alto Neuroscience, Inc.

Negatives

• This filing, a Schedule 13G, does not contain information typically categorized as negatives regarding the issuer's operations or financial performance.

Risks

• This Schedule 13G filing does not detail specific operational, financial, or strategic risks pertaining to Alto Neuroscience, Inc.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Alto Neuroscience, Inc.'s future performance or strategic direction.

Management Comments

• Joseph Edelman, Managing Member of Perceptive Advisors LLC and Perceptive Life Sciences Master Fund, Ltd., certified that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The disclosure of a significant stake by Perceptive Advisors, a specialized life sciences investment firm, indicates continued investor interest and potential validation within the biotechnology and neuroscience sectors. Such investments can draw attention to the issuer within the broader industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a stake may instill greater confidence and potentially attract further investor interest, positively impacting share value.
• Company Management: A large institutional investor may increase scrutiny on management decisions and strategic direction, while also providing a potential source of support or expertise.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Perceptive Advisors, has taken a 7.3% stake in Alto Neuroscience. This signals a vote of confidence from a specialized life sciences fund, which can be a positive indicator for the company's prospects. While this alone doesn't warrant a 'buy' without further fundamental analysis of Alto Neuroscience's financials and pipeline, it suggests the stock is worth holding for existing investors and warrants further investigation for potential new investors, hence a 'hold' recommendation with a positive bias.

Keywords

Alto Neuroscience, Perceptive Advisors, Joseph Edelman, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Biotechnology Investment